Wedbush Securities Inc Cytom X Therapeutics, Inc. Transaction History

Wedbush Securities Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 01, 2019	SELL	$9.35 - $11.41 $171,853 - $209,715	-18,380 Closed	0 $0
Q1 2019 Apr 17, 2019	SELL	$9.5 - $19.16 $66,262 - $133,641	-6,975 Reduced 27.51%	18,380 $198,000
Q4 2018 Jan 31, 2019	BUY	$12.69 - $18.61 $24,111 - $35,359	1,900 Added 8.1%	25,355 $383,000
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $184,459 - $270,042	10,225 Added 77.29%	23,455 $434,000
Q2 2018 Aug 03, 2018	BUY	$21.38 - $29.68 $282,857 - $392,666	13,230 New	13,230 $302,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.